Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1765-1774

  Urasaki, Yasuyo ^a   Nori, Mamoru ^a   Iwata, Satoshi ^a   Sasaki, Takahiro ^a   Hosono, Osamu ^a   Kawasaki, Hiroshi ^a   Tanaka, Hirotoshi ^a   Dang, Nam H ^b   Ikeda, Eiji ^c   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Collagen induced arthritis; Costimulation; Macrophages; Proinflammatory cytokine; Rheumatoid arthritis; Roxithromycin; T cells

Indexed keywords

CD28 ANTIGEN; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROLIDE; MONOCLONAL ANTIBODY CD3; ROXITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTHRITIS; ARTICLE; ASTHMA; BRONCHIOLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; LEUKOCYTE MIGRATION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOPSY, NEEDLE; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; PROBABILITY; ROXITHROMYCIN; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944458849     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Nelson S, Summer WR, Terry PB, Warr GA, Jakab GJ. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection. Am Rev Respir Dis 1987;136:1207-12.
2. Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment on patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993;147:153-9.
3. Miyatake H, Suzuki K, Taki F, Takagi K, Satake T. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung 1991;41:552-6.
4. Yokota T, Suzuki E, Arai K. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Drugs Exp Clin Res 1988;14:495-500.
5. Fraschini F, Scaglione F, Ferrara F, Marelli O, Braga PC, Teodori F Evaluation of the immunostimulating activity of erythromycin in man. Chemotherapy 1986;32:286-90.
6. Mikasa K, Sawaki M, Konishi M, et al. The effect of erythromycin treatment on natural killer cell activity in patients with chronic lower respiratory tract infections. Kansenshogaku Zasshi 1989;63:811-5.
7. Ras GJ, Anderson R, Eftychis HA, et al. Chemoprophylaxis with erythromycin stearate or amoxycillin in patients with chronic bronchitis - effects on cellular and humoral immune functions. S Afr Med J 1984;66:955-8.
8. Aho P, Mannisto PT. Effects of two erythromycins, doxycycline and phenoxymethylpenicillin, on human leucocyte chemotaxis in vitro. J Antimicrob Chemother 1988;21:29-32.
9. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989;159:966-73.
10. Yoshimura T, Kurita C, Yamazaki F, et al. Effect of roxithromycin on proliferation of peripheral blood mononuclear cells and production of lipopolysaccharide-induced cytokines. Biol Pharm Bull 1995;18;876-81.
11. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin, A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989;37;8-41.
12. Noma T, Hayashi M, Yoshizawa I, Aoki K, Shikishima Y, Kawano Y. A comparative investigation of the restorative effects of roxithromycin on neutrophil activities. Int J Immunopharmacol 1998;20:615-24.
13. Wakita H, Tokura Y, Furukawa F, Takigawa M. The macrolide antibiotic roxithromycin suppresses IFN-gamma-mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull 1996;19:224-7.
14. Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Inhibition of human T-lymphocyte activation by macrolide antibiotic roxithromycin. Life Sci 1992;51:L231-6.
15. Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M, Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994;105:308-16.
16. Robey E, Allison JP, T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 1995;16:306-10.
17. Green JM, Noel PJ, Sperling AI, et al. Absence of B-7 dependent responses in CD28-deficient mice. Immunity 1994;1:501-8.
18. Gimmi CD, Freeman GJ, Gribben JG, et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991;88:6575-9.
19. Morimoto C, Torimoto Y, Levinson G, et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells, J Immunol 1989;143:3430-9.
20. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990;144:4092-100.
21. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993;90:4586-90.
22. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985;312:1405-11.
23. Iwata S, Yamaguchi N, Munakata Y, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999;11:417-26.
24. Rosloniec EF, Cremer M, Kang A, Myers LK. Collagen-induced arthritis. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York: Wiley; 1996:15.5.1-24.
25. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM, Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991;12:392-5.
26. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-57.
27. Johnston RB Jr. Current concepts: immunology. Monocytes and macrophages. N Engl J Med 1988;318:747-52.
28. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Clin Exp Immunol 1997;107:507-12.
29. Asano K, Kamakazu K, Hisamitsu T, Suzaki H, Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. Int Immunopharmacol 2001;11:1913-21.
30. Morikawa K, Zhang J, Nonaka M, Morikawa S, Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002;19:53-9.
31. Suzaki H, Asano K, Ohki S, Kanai K, Mizutani T, Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm 1999;8:199-204.
32. Iino Y, Toriyama M, Kudo K, Natori Y, Yuo A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl 1992;157:16-20.
33. Guchelaar HJ, Schultz MJ, van der Poll T, Koopmans RP. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. Fundam Clin Pharmacol 2002;15:419-24.
34. Itkin IH, Menzel ML. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effect of erythromycin on tumour necrosis factor-alpha and interleukin-6 production. J Allergy 1970;45:146-62.
35. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
36. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997;158:3539-44.
37. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
38. Amrani Y, Chen H, Panettieri RA Jr. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir Res 2000;1:49-53.
39. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84.
40. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
41. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
42. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptonFc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
43. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
44. Kam LY, Targan SR. TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opin Pharmacother 2000;1:615-22.
45. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-50.
46. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
47. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20:247-59.
48. Jacobsohn DA. Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 2002;11:1271-80.
49. Negrusz-Kawecka, M. The role of TNF-alpha in the etiopathogenesis of heart failure. Pol Merkuriusz Lek 2002;12:69-72.
50. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppress Castleman's disease-like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;21:304-11.